Abstract
The major stepping stone laid towards the identification of high-risk endometrial cancers was made by the Cancer Genome Atlas in 2013 when the four distinct molecular subtypes were initially described. This improved risk stratification for women with endometrial cancer and ignited a major interest which led to further research on the prognostic and predictive value of molecular subtyping. Through the elaboration of ProMisE, molecular risk assignment using surrogate markers became practical and accessible to most pathology laboratories. The p53abn molecular subtype of endometrial cancer is responsible for the worst outcomes. This review aims to provide an in-depth understanding of the characteristics of these aggressive ECs, summarizing up-to-date literature regarding the prognostic and predictive implications, as well as present and future treatment directions.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
